Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06908031

SCRT + mFOLFOX6 + PD-1 Antibody + Targeted Therapy for HIgh-Risk pMMR/MSS Rectal Cancer (CRIT)

Short-Course Radiotherapy Combined With mFOLFOX6, PD-1 Antibody and Cetuximab (for RAS/BRAF Wild-Type)/Bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma: a Prospective, Multicenter Phase II Study

Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University

Conditions High-Risk Cancer MSS Rectal Adenocarcinoma

Interventions Bevacizumab Cetuximab PD-1 monoclonal antibody Short-Course Radiotherapy Surgical resection mFOLFOX6 regimen

Updated 2 times since 2025 Last updated: May 10, 2025 Started: Apr 2, 2025 Primary completion: Apr 1, 2027 Completion: Apr 1, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates High-Risk Cancer and MSS and is currently actively recruiting participants. Sixth Affiliated Hospital, Sun Yat-sen University leads this study, which shows 2 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

2 versions recorded

Jun 2025 — Present [monthly]

Recruiting PHASE2

Phase: PHASE3 → PHASE2
May 2025 — Jun 2025 [monthly]

Recruiting PHASE3

First recorded

Apr 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sixth Affiliated Hospital, Sun Yat-sen University

Data source: Sixth Affiliated Hospital, Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China